Day One Biopharmaceuticals, INC 8-K filings

Servier Pharmaceuticals has successfully completed its acquisition of Day One Biopharmaceuticals through a tender offer and subsequent merger, with the transaction closing on April 23, 2026.

Servier Pharmaceuticals will acquire Day One Biopharmaceuticals for $21.50 per share in cash, valuing the company at approximately $2.5 billion.

Day One Biopharmaceuticals' OJEMDA received a positive opinion from the European Medicines Agency's CHMP for conditional marketing authorization in relapsed or refractory BRAF-altered pediatric low-grade glioma.

Day One Biopharmaceuticals announced robust Q4 and full-year 2025 financial results, driven by strong OJEMDA sales, and reaffirmed its 2026 revenue guidance and pipeline progress.

Day One Biopharmaceuticals announced preliminary unaudited 2025 OJEMDA net product revenue of $155.4 million, representing 172% year-over-year growth, and projected 2026 revenue of $225-$250 million.

Day One Biopharmaceuticals successfully acquired Mersana Therapeutics, adding clinical-stage antibody drug conjugate Emi-Le and expanding its oncology pipeline.

Day One Biopharmaceuticals announced positive three-year follow-up data for OJEMDA (tovorafenib) in pediatric low-grade glioma, alongside strong Q3 2025 revenue growth and raised full-year guidance.

Day One Biopharmaceuticals will acquire Mersana Therapeutics for up to $285 million, expanding its oncology portfolio with a novel ADC for rare cancers.

Day One Biopharmaceuticals reported strong third-quarter 2025 financial results, with OJEMDA net product revenue increasing 15% sequentially and full-year guidance raised.

Day One Biopharmaceuticals' Board approved an option repricing for certain directors and employees, including named executive officers, to retain and motivate key talent.

Day One Biopharmaceuticals announced robust second-quarter 2025 financial results, driven by significant growth in OJEMDA net product revenue and reaffirmed full-year guidance.

Day One Biopharmaceuticals, Inc. announced that its stockholders approved the election of two Class I Directors, the ratification of PricewaterhouseCoopers LLP as its independent auditor, and the advisory vote on executive compensation at its 2025 Annual Meeting.

Day One Biopharmaceuticals announces first quarter 2025 financial results, highlighting a 16% increase in OJEMDA prescriptions and $30.5 million in net product revenue.

Day One Biopharmaceuticals announces positive financial results for Q4 and full year 2024, driven by OJEMDA sales and corporate progress.

Day One Biopharmaceuticals reported preliminary unaudited 2024 OJEMDA net product revenue of approximately $57.2 million and ended the year with approximately $531.7 million in cash, cash equivalents, and short-term investments.

Day One Biopharmaceuticals announces the retirement of its Head of Research & Development, Samuel Blackman, effective at the end of 2024.

Day One Biopharmaceuticals announced a profitable third quarter of 2024, driven by strong sales of OJEMDA and strategic licensing agreements.

Day One Biopharmaceuticals announced positive second quarter 2024 financial results, highlighted by $8.2 million in initial net product revenue from OJEMDA and strategic pipeline advancements.

Day One Biopharmaceuticals, Inc. has successfully completed a $175 million private placement to fund commercial capabilities, research and development, and potential strategic acquisitions.

Day One Biopharmaceuticals has granted Ipsen exclusive rights to commercialize tovorafenib outside the U.S., securing an upfront payment and potential milestone payments totaling up to $461 million.

Day One Biopharmaceuticals has secured an exclusive worldwide license, excluding Greater China, for a novel antibody-drug conjugate, DAY301, targeting PTK7, paying $55 million upfront and potentially up to $1.15 billion in milestones.

Day One Biopharmaceuticals has updated its corporate presentation and announced changes to its pivotal Phase 3 FIREFLY-2 trial for tovorafenib in pediatric low-grade glioma.

Day One Biopharmaceuticals has sold its Rare Pediatric Disease Priority Review Voucher for $108 million, strengthening its financial position.

Day One Biopharmaceuticals held its 2024 Annual Meeting of Stockholders, where key proposals including the election of directors and ratification of the company's auditor were approved.

Day One Biopharmaceuticals reported its first quarter 2024 financial results, highlighted by the launch of OJEMDA and ongoing clinical trial progress.

Day One Biopharmaceuticals' OJEMDA (tovorafenib) has received accelerated FDA approval for treating relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG), the most common form of childhood brain tumor.

Day One Biopharmaceuticals has amended its license agreement with Viracta Therapeutics, making a $5 million payment to reduce future obligations related to a potential Priority Review Voucher.

Day One Biopharmaceuticals announced its fourth quarter and full year 2023 financial results, highlighting progress with tovorafenib and a strong cash position.

Day One Biopharmaceuticals has appointed Habib Dable and Dr. William Grossman to its Board of Directors, bringing significant oncology expertise to the company.